Physician profile
Michael D Gerber
NPI 1639607757
$5,551.76
in general payments reported to CMS, 2019-2025
20 companies · $1,095 in 2025
The $1,095 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $955 · 2022: $1,310 · 2023: $1,306 · 2024: $887 · 2025: $1,095.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,214 · Education: $72.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,214.41 |
| Education | $72.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $922.55 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $811.65 | 2021-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $800.13 | 2021-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $722.74 | 2022-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Lundbeck LLC | $446.42 | 2021-2023 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $373.84 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Sunovion Pharmaceuticals INC. | $267.88 | 2021-2022 | |
| Axsome Therapeutics, INC. | $237.73 | 2023-2025 | Auvelity |
| Vanda Pharmaceuticals INC. | $210.13 | 2021-2025 | Fanapt, Hetlioz |
| Alkermes, INC. | $192.84 | 2022-2025 | Aristada, Lybalvi |
| Neurocrine Biosciences, INC. | $180.72 | 2022-2025 | Ingrezza |
| Indivior INC. | $157.16 | 2022-2024 | Sublocade, Perseris |
| Ironshore Pharmaceuticals INC. | $65.53 | 2022-2024 | |
| E.R. Squibb & Sons, L.L.C. | $50.06 | 2024-2025 | Cobenfy |
| Collegium Pharmaceutical, INC. | $30.38 | 2025 | Jornay Pm |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harmony Biosciences LLC | $18.45 | 2024 | |
| Corium, LLC | $17.32 | 2024 | Azstarys |
| Acadia Pharmaceuticals INC | $16.01 | 2023 | Nuplazid |
| Tris Pharma INC | $15.51 | 2025 | |
| Supernus Pharmaceuticals, INC. | $14.71 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Gerber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.